Physician profile
Farah Soliman
NPI 1316154602
$2,214.18
in general payments reported to CMS, 2019-2025
24 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $86.34 · 2022: $67.26 · 2023: $411 · 2024: $771 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $251.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $211.16 | 2023-2025 | |
| Novo Nordisk INC | $202.77 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $190.97 | 2025 | Mo.Ma Ultra |
| Amgen INC. | $142.42 | 2021-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $134.72 | 2024-2025 | |
| Abbott Laboratories | $134.52 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $134.38 | 2023-2025 | |
| Boston Scientific Corporation | $121.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $106.26 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $96.25 | 2025 | Gemtesa |
| Pfizer INC. | $92.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.87 | 2023-2025 | Jardiance |
| Dexcom, INC. | $46.05 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $41.24 | 2023-2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $34.68 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $34.51 | 2023-2024 | Cologuard Collection Kit |
| Bolton Medical INC | $32.57 | 2024 | Treo Abdominal Stent-Graft System |
| Glaxosmithkline, LLC. | $32.41 | 2023 | Shingrix, Arexvy |
| Lundbeck LLC | $29.28 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.83 | 2023 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $20.61 | 2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $18.73 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $12.76 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.